Berotralstat to reimbursed in the Netherlands

The Zorginstituut Nederland has issued a positive recommendation on berotralstat (Orladeyo) for the routine prevention of HAE attacks in patients aged 12 years and over, according to a statement shared with the HAEi.

The pharmaceutical company BioCryst notes that this means the medicine is now reimbursed in all major European countries.

Abid Karim, General Manager of Europe at BioCryst, said: “From day one, our mission has been to bring Orladeyo to as many people living with hereditary angioedema as possible. Securing reimbursement in the Netherlands is a proud moment for our team as it means that patients and physicians across all major European countries now have access to a modern, oral prophylactic option to help prevent HAE attacks.”

(Source: BioCryst)